Compare Amylx Pharmaceuticals Inc (AMLX) vs ProShares UltraShort Bloomberg Natural Gas ETF (KOLD) Price & Performance

AMLX trades at $17.77, down 3.32% today, with a bullish technical signal from moving averages and strong analyst support. The company is in a pivotal phase with key Phase 3 data for avexitide expected in Q3 2026, targeting a potential 2027 launch. Financially, it shows significant losses with negative ROE and ROA, but cash flow from financing activities provides runway. Recent news highlights clinical progress and conference presentations, alongside ongoing class action settlement discussions.

The outlook hinges on successful clinical trial outcomes, particularly avexitide's Phase 3 readout, which could drive substantial upside toward the $30.50 consensus price target. However, high execution risk, persistent cash burn, and legal overhangs pose threats to near-term stability. Investor sentiment remains cautiously optimistic given the 90.9% buy rating from analysts, but the stock is speculative until profitability milestones are achieved.

KOLD is trading at $26.96, up 4.25% with a bullish technical signal supported by moving averages. The stock faces resistance at $27-$29 while finding support at $25-$23 levels. Recent natural gas market volatility driven by weather patterns and LNG demand creates trading opportunities for this bearish natural gas ETF. The RSI at 73.40 indicates potential overbought conditions near-term.

As a tactical trading instrument, KOLD offers exposure to inverse natural gas price movements amid heightened energy market volatility. Key catalysts include weather-driven demand shifts and geopolitical developments affecting LNG exports. Risk factors include sudden natural gas price spikes and changing supply-demand dynamics that could pressure the fund's inverse positioning.